All202320222020201920182017201620152014 Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.February 2, 2022 Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138April 21, 2020 Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in DepressionSeptember 12, 2019Navitor Expands Leadership Team with Appointment of James Randall Owen, M.D. as Chief Medical OfficerJuly 15, 2019Navitor Pharmaceuticals Announces Peer-Reviewed Publication in Journal of Clinical Investigation Highlighting Rapid Antidepressant Effects of NV-5138April 16, 2019Navitor Pharmaceuticals Announces Peer-Reviewed Publication Detailing the Discovery and Development of NV-5138March 11, 2019Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, A Novel mTORC1 Activator in Patients with Treatment-Resistant DepressionJanuary 24, 2019 Navitor Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare ConferenceNovember 20, 2018Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive OfficerAugust 2, 2018Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant DepressionJune 26, 2018Navitor Pharmaceuticals to Present at UBS Global Healthcare ConferenceMay 17, 2018Navitor Pharmaceuticals to Present at Cowen and Company Healthcare ConferenceMarch 7, 2018 Scientific Poster: Sestrin2 modulator NV-5138, shows ketamine-like rapid antidepressant effects via direct activation of mTORC1 signalingNovember 15, 2017Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017November 15, 2017Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and ActivityNovember 9, 2017 No Press Releases in 2016January 1, 2016 Navitor Pharmaceuticals Announces $33 Million Series B FinancingDecember 18, 2015Navitor Pharmaceuticals’ Scientific Founder Makes Landmark Discovery of the Molecular Sensor for the Amino Acid LeucineOctober 8, 2015Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory BoardSeptember 1, 2015Navitor Pharmaceuticals Appoints Paul Friedman, MD, to Its Board of DirectorsJune 15, 2015Navitor Pharmaceuticals Selected as “Hottest Startup” in Healthcare at New England Venture Capital Association’s 2015 NEVY AwardsMay 14, 2015 Navitor Pharmaceuticals Appoints Eddine Saiah, PhD, as Vice President of Drug DiscoveryNovember 20, 2014FierceBiotech names Navitor Pharmaceuticals as one of its “Fierce 15” Biotech Companies of 2014September 22, 2014Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing for Novel Drug Discovery Targeting Cellular Nutrient Signaling to Treat Chronic Diseases and Rare DisordersJune 19, 2014
